What Is Step Therapy with Calibrate?

How Step Therapy Works in Weight Management

Step therapy is a utilization-management strategy that insurers use to control prescription drug spending. The patient must try (and fail) a formulary-preferred medication before the plan authorizes a more expensive one. The American Medical Association has formally opposed mandatory step therapy protocols that delay clinically appropriate care [1].

The Basic Sequence

A typical obesity-medication step-therapy protocol starts with generic agents. Metformin, though not FDA-approved for weight loss alone, is frequently positioned as a first step because of its low cost and documented modest weight-reducing effect of approximately 2-3% body weight in patients with insulin resistance [2]. Orlistat (Xenical/Alli) may also appear as a required first step; its FDA approval for long-term weight management dates to 1999 [3].

Why Insurers Require It

Insurers frame step therapy as evidence-based cost containment. A 2019 analysis published in the Journal of Managed Care & Specialty Pharmacy found that step-therapy protocols reduced plan spending on specialty medications by 8-23% annually [4]. For GLP-1 receptor agonists, the math is straightforward: Wegovy carries a list price exceeding $1,300 per month, while generic metformin costs under $10 [5].

Where Calibrate Fits

Calibrate's metabolic reset program pairs GLP-1 prescriptions with metabolic health coaching, food logging, and exercise guidance. When a patient's insurance plan imposes step therapy, Calibrate's clinical team documents the patient's medication history, gathers lab results, and files prior-authorization paperwork. The program does not bypass step therapy. It accelerates the documentation process so the required steps are completed with proper clinical records.

Medications Commonly Required Before GLP-1 Approval

Insurance formularies vary, but most plans that cover anti-obesity medications impose a two- or three-step ladder before approving a GLP-1 agonist. The Obesity Medicine Association's 2024 clinical practice guidelines list six FDA-approved pharmacotherapy options for chronic weight management [6].

First-Step Agents

Phentermine, approved for short-term use (up to 12 weeks), is the most widely prescribed first-step medication [7]. Naltrexone-bupropion ER (Contrave) is another common first-step drug; in the COR-I trial (N=1,742), it produced 6.1% mean body-weight loss at 56 weeks versus 1.3% for placebo [8]. Phentermine-topiramate ER (Qsymia) showed 9.8% weight loss at the top dose in the CONQUER trial (N=2,487), making it the most effective non-GLP-1 option [9].

Second-Step Agents

Some plans place liraglutide 3.0 mg (Saxenda) as a second step before approving semaglutide 2.4 mg (Wegovy) or tirzepatide (Zepbound). In the SCALE Obesity and Prediabetes trial (N=3,731), liraglutide 3.0 mg achieved 8.0% mean weight loss at 56 weeks compared with 2.6% for placebo [10]. Plans that require this intermediate step typically mandate a 90-day trial.

Third-Step (Target) Agents

The GLP-1 and dual GIP/GLP-1 agonists sit at the top of most formulary ladders. Semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks in the STEP 1 trial (N=1,961) versus 2.4% for placebo [11]. Tirzepatide at the 15 mg dose produced 20.9% weight loss at 72 weeks in SURMOUNT-1 (N=2,539) versus 3.1% for placebo [12].

The Prior-Authorization Process for GLP-1s

Prior authorization (PA) is the gate that step therapy feeds into. After documenting failure on the required first-step drugs, the prescriber submits a PA request to the insurer. The Centers for Medicare & Medicaid Services defines prior authorization as a decision by a health plan that a service or medication is medically necessary before the patient receives it [13].

What the PA Request Includes

A complete PA packet for a GLP-1 obesity medication typically requires: the patient's BMI (must be 30 or above, or 27 or above with a weight-related comorbidity per FDA labeling), documentation of each failed step-therapy medication including dates and reasons for discontinuation, relevant lab work (HbA1c, fasting insulin, lipid panel), and a letter of medical necessity from the prescribing clinician [3].

Timeline and Approval Rates

Commercial plans must respond to a standard PA request within 5-15 business days, depending on state law. Urgent requests require a 72-hour turnaround under most state regulations. A 2023 AMA survey found that 94% of physicians reported care delays due to prior authorization, and 33% reported that PA led to a serious adverse event for a patient in their care [14].

Calibrate's PA Workflow

Calibrate assigns a care team that handles the administrative burden. The clinician reviews the patient's medication history during the initial consultation, identifies which step-therapy requirements apply, and builds the PA case before the patient fills a single prescription. If the patient has already tried and failed qualifying medications with a prior provider, those records can satisfy step-therapy requirements without repeating the drug trial. This is a critical time-saving detail that many patients overlook.

Step-Therapy Exceptions and Appeals

Not every patient needs to complete every step. Federal and state laws increasingly protect patients from clinically harmful step-therapy delays.

State Exception Laws

As of 2025, more than 30 states have enacted step-therapy reform laws that require insurers to grant exceptions when a required medication is contraindicated, has caused an adverse reaction, or is expected to be ineffective based on the patient's clinical profile [15]. The Endocrine Society has specifically advocated for step-therapy reform in endocrine and metabolic disease management, calling mandatory fail-first protocols "a barrier to evidence-based care" [16].

How to File an Exception

A step-therapy exception request must include clinical justification. Acceptable grounds typically include: documented allergy or intolerance to the required first-step drug, a medical contraindication (for example, phentermine is contraindicated in patients with uncontrolled hypertension or a history of cardiovascular disease) [7], prior adequate trial of the step-therapy drug through a different provider or health plan, or the patient's condition is expected to worsen during the step-therapy trial period.

The Appeals Process

If the initial PA or exception request is denied, federal law under the ACA requires at least one level of internal appeal and one level of external review [17]. The external review must be conducted by an independent review organization. Dr. Scott Hagan, an internal medicine physician at the VA Puget Sound, has noted: "Step therapy can be appropriate when the evidence supports equivalent efficacy, but when we have clear data showing one agent is superior, the fail-first requirement becomes an obstacle to optimal care" [18].

Clinical Risks of Mandatory Step Therapy

Delayed access to effective treatment is not a neutral outcome. The American Society for Metabolic and Bariatric Surgery (ASMBS) issued a position statement warning that mandatory step therapy for obesity medications may contribute to disease progression during the forced trial period [19].

Weight Cycling and Metabolic Harm

Patients who lose modest weight on a first-step agent and then regain it before transitioning to a GLP-1 experience weight cycling. A 2017 meta-analysis in Obesity Reviews (N=158,063 across 36 cohorts) found that weight cycling was associated with increased all-cause mortality (HR 1.41, 95% CI 1.27-1.57) [20]. Short-duration trials on marginally effective medications may worsen metabolic outcomes rather than improve them.

Mental Health Consequences

Repeated medication failures erode patient motivation. The ACTION study (N=3,008) found that 82% of adults with obesity viewed their weight as entirely their own responsibility, and only 44% considered obesity a chronic disease [21]. Forcing patients through sequential failures reinforces the false narrative that their weight is a willpower problem rather than a metabolic one.

Cardiovascular Risk Window

For patients with existing cardiovascular risk factors, treatment delays carry measurable danger. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, without diabetes [22]. Delaying access to semaglutide in this population means delaying a proven cardiovascular risk reduction.

How Calibrate Handles Step Therapy Differently Than Standard Prescribers

Calibrate's program structure addresses several pain points that make step therapy particularly frustrating in traditional clinical settings.

Proactive Documentation

A standard primary-care visit lasts 15-18 minutes. In that window, building a step-therapy exception case is nearly impossible. Calibrate's asynchronous care model allows clinicians to spend more time reviewing records, compiling documentation, and drafting PA letters. The program collects a detailed medication history at intake specifically to identify which step-therapy requirements the patient has already satisfied.

Metabolic Health Coaching During Step Periods

If a patient must complete a 60- or 90-day trial on a first-step agent, Calibrate provides concurrent lifestyle coaching. The program's approach aligns with the 2022 American Gastroenterological Association (AGA) clinical practice guideline, which recommends combining pharmacotherapy with lifestyle intervention for adults with a BMI of 30 or greater [23]. This means the step-therapy period is not wasted time. The patient builds behavioral habits that amplify the GLP-1's effect once approved.

Tracking Outcomes to Strengthen the PA Case

During the first-step medication trial, Calibrate clinicians track weight, metabolic labs, and patient-reported outcomes. If the medication produces inadequate results, that data becomes the clinical evidence for the PA request. A well-documented insufficient response is far more persuasive to an insurance reviewer than a vague statement of "patient did not respond."

What to Do If Your Step-Therapy Request Is Denied

Denials happen frequently. The AMA reports that physicians submit an average of 45 prior-authorization requests per week, and one in four is initially denied [14].

Gather Your Documentation

Collect pharmacy records showing fill dates and durations for all previously tried medications. Request clinical notes from any prior provider who prescribed a weight-management drug. Obtain labs that demonstrate metabolic dysfunction (elevated HbA1c, fasting insulin, triglycerides) to strengthen the case for medical necessity. The National Institutes of Health defines overweight and obesity as chronic diseases influenced by genetic, metabolic, behavioral, and environmental factors [24].

Request a Peer-to-Peer Review

Most insurers allow the prescribing clinician to speak directly with the plan's medical director. This peer-to-peer review is often the fastest way to overturn a denial. Calibrate clinicians can participate in these calls on the patient's behalf.

File an External Appeal

If internal appeals fail, request external review through your state's insurance department. The Affordable Care Act guarantees this right for all non-grandfathered health plans [17]. External reviewers overturn insurer denials in approximately 40-60% of cases, according to data from multiple state insurance departments.

Medicare, Medicaid, and Step Therapy for Obesity Drugs

Coverage for anti-obesity medications varies dramatically across payer types.

Medicare Part D

Historically, Medicare Part D excluded coverage for anti-obesity medications under the statutory "weight loss" exclusion. The Treat and Reduce Obesity Act, if enacted, would lift this ban [25]. As of 2026, Medicare Part D has begun covering semaglutide and tirzepatide for obesity following the inclusion of these agents in updated CMS guidance for members with cardiovascular disease risk.

Medicaid

Medicaid coverage varies by state. As of 2025, fewer than half of state Medicaid programs cover any FDA-approved anti-obesity medication [6]. States that do provide coverage almost universally impose step-therapy requirements, often demanding failure on two agents before approving a GLP-1.

Employer-Sponsored Plans

Large employer plans increasingly cover GLP-1s for obesity, driven by data showing reduced downstream healthcare costs. The CDC estimates that the annual medical cost of obesity in the United States is $173 billion, with obese individuals paying $1,861 more per year in medical costs than those at a healthy weight [26].